1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002. 288:321–333.
2. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002. 360:942–944.
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004. 291:1701–1712.
4. Choi H, Lee HK, Park HM. The Korean menopausal women`s attitudes and awareness on menopause: results of Korean gallup epidemiologic survey on menopause and HRT. J Korean Soc Menopause. 2003. 9:36–43.
5. Deeks A, Zoungas S, Teede H. Risk perception in women: a focus on menopause. Menopause. 2008. 15:304–309.
6. MacLennan AH, Sturdee DW. WHI, WHI, WHI? Climacteric. 2004. 7:221–224.
7. Gambrell RD Jr. The women's health initiative reports in perspective: facts or fallacies? Climacteric. 2004. 7:225–228.
8. Pedersen AT, Ottesen B. Issues to debate on the Women's Health Initiative (WHI) study. Epidemiology or randomized clinical trials--time out for hormone replacement therapy studies? Hum Reprod. 2003. 18:2241–2244.
9. Heitmann C, Greiser E, Dören M. The impact of the Women's Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause. 2005. 12:405–411.
10. Scheid DC, Coleman MT, Hamm RM. Do perceptions of risk and quality of life affect use of hormone replacement therapy by postmenopausal women? J Am Board Fam Pract. 2003. 16:270–277.
11. Sturmberg JP, Pond DC. Impacts on clinical decision making - changing hormone therapy management after the WHI. Aust Fam Physician. 2009. 38:249–251. 253–255.